Economic impact of treatments for controlling symptoms associated with rhinitis

An evaluation of Narivent® vs standard therapy

Valerio Damiani, Dilyana Vicheva, Angelo Camaioni, Claudio Viti, Giulia Schillani, Giada Morpurgo, Antonella Silvia Scirè, Dario Gregori

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rationale and aim: Upper airway disorders, like allergic and non-allergic rhinitis, are common nasal conditions affecting millions of individuals worldwide. The prevalence of allergic rhinitis (AR), in particular, has been increasing in the last decades. The pervasiveness of this disorder therefore imposes a large burden both on individual patients and the society. A wide range of drugs exists for symptomatic treatment of rhinitis, such as corticosteroids, decongestants, and antihistamines, but standard therapies are often associated with several side effects. A new class of medical devices, based on bio-mechanically innovative triggers, has been proven to have a good clinical effectiveness with lower adverse reactions, particularly over prolonged administration periods. The present study aims at evaluating the economic impact of rhinitis, with respect to direct and indirect costs, and analysing the use of the medical device Narivent® compared to standard therapies to manage the symptoms of this illness. Methods: Via a Monte Carlo simulation study, data on disease prevalence, drug prescription and cost of both the specific therapeutic approach and the adverse events treatment will be combined to provide an estimate of the overall cost of the pharmacotherapy as compared with Narivent®. Results: Lowering the impact of adverse reactions related to standard therapy through the use of novel therapeutic approaches like Narivent®, might reduce the overall burden of rhinitis by about 5 billion per year. Conclusion: The use of the medical device Narivent®, as an alternative approach to manage symptoms associated with rhinitis, may contribute to bring down its costs by about 3.5% yearly as compared to the standard therapy.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalOpen Medical Devices Journal
Volume4
Issue numberSPL. ISS.
DOIs
Publication statusPublished - 2012

Fingerprint

Rhinitis
Economics
Costs
Drug therapy
Costs and Cost Analysis
Equipment and Supplies
Therapeutics
Nasal Decongestants
Drug Prescriptions
Drug Costs
Histamine Antagonists
Therapeutic Uses
narivent
Nose
Adrenal Cortex Hormones
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Allergic rhinitis costs
  • Burden of rhinitis
  • Cost impact analysis
  • Non allergic rhinitis costs

ASJC Scopus subject areas

  • Biomedical Engineering
  • Medicine (miscellaneous)

Cite this

Economic impact of treatments for controlling symptoms associated with rhinitis : An evaluation of Narivent® vs standard therapy. / Damiani, Valerio; Vicheva, Dilyana; Camaioni, Angelo; Viti, Claudio; Schillani, Giulia; Morpurgo, Giada; Scirè, Antonella Silvia; Gregori, Dario.

In: Open Medical Devices Journal, Vol. 4, No. SPL. ISS., 2012, p. 61-65.

Research output: Contribution to journalArticle

Damiani, V, Vicheva, D, Camaioni, A, Viti, C, Schillani, G, Morpurgo, G, Scirè, AS & Gregori, D 2012, 'Economic impact of treatments for controlling symptoms associated with rhinitis: An evaluation of Narivent® vs standard therapy', Open Medical Devices Journal, vol. 4, no. SPL. ISS., pp. 61-65. https://doi.org/10.2174/1875181401204010061
Damiani, Valerio ; Vicheva, Dilyana ; Camaioni, Angelo ; Viti, Claudio ; Schillani, Giulia ; Morpurgo, Giada ; Scirè, Antonella Silvia ; Gregori, Dario. / Economic impact of treatments for controlling symptoms associated with rhinitis : An evaluation of Narivent® vs standard therapy. In: Open Medical Devices Journal. 2012 ; Vol. 4, No. SPL. ISS. pp. 61-65.
@article{dca246551d1b41d593fcba6037608b05,
title = "Economic impact of treatments for controlling symptoms associated with rhinitis: An evaluation of Narivent{\circledR} vs standard therapy",
abstract = "Rationale and aim: Upper airway disorders, like allergic and non-allergic rhinitis, are common nasal conditions affecting millions of individuals worldwide. The prevalence of allergic rhinitis (AR), in particular, has been increasing in the last decades. The pervasiveness of this disorder therefore imposes a large burden both on individual patients and the society. A wide range of drugs exists for symptomatic treatment of rhinitis, such as corticosteroids, decongestants, and antihistamines, but standard therapies are often associated with several side effects. A new class of medical devices, based on bio-mechanically innovative triggers, has been proven to have a good clinical effectiveness with lower adverse reactions, particularly over prolonged administration periods. The present study aims at evaluating the economic impact of rhinitis, with respect to direct and indirect costs, and analysing the use of the medical device Narivent{\circledR} compared to standard therapies to manage the symptoms of this illness. Methods: Via a Monte Carlo simulation study, data on disease prevalence, drug prescription and cost of both the specific therapeutic approach and the adverse events treatment will be combined to provide an estimate of the overall cost of the pharmacotherapy as compared with Narivent{\circledR}. Results: Lowering the impact of adverse reactions related to standard therapy through the use of novel therapeutic approaches like Narivent{\circledR}, might reduce the overall burden of rhinitis by about 5 billion per year. Conclusion: The use of the medical device Narivent{\circledR}, as an alternative approach to manage symptoms associated with rhinitis, may contribute to bring down its costs by about 3.5{\%} yearly as compared to the standard therapy.",
keywords = "Allergic rhinitis costs, Burden of rhinitis, Cost impact analysis, Non allergic rhinitis costs",
author = "Valerio Damiani and Dilyana Vicheva and Angelo Camaioni and Claudio Viti and Giulia Schillani and Giada Morpurgo and Scir{\`e}, {Antonella Silvia} and Dario Gregori",
year = "2012",
doi = "10.2174/1875181401204010061",
language = "English",
volume = "4",
pages = "61--65",
journal = "Open Medical Devices Journal",
issn = "1875-1814",
publisher = "Bentham Science Publishers",
number = "SPL. ISS.",

}

TY - JOUR

T1 - Economic impact of treatments for controlling symptoms associated with rhinitis

T2 - An evaluation of Narivent® vs standard therapy

AU - Damiani, Valerio

AU - Vicheva, Dilyana

AU - Camaioni, Angelo

AU - Viti, Claudio

AU - Schillani, Giulia

AU - Morpurgo, Giada

AU - Scirè, Antonella Silvia

AU - Gregori, Dario

PY - 2012

Y1 - 2012

N2 - Rationale and aim: Upper airway disorders, like allergic and non-allergic rhinitis, are common nasal conditions affecting millions of individuals worldwide. The prevalence of allergic rhinitis (AR), in particular, has been increasing in the last decades. The pervasiveness of this disorder therefore imposes a large burden both on individual patients and the society. A wide range of drugs exists for symptomatic treatment of rhinitis, such as corticosteroids, decongestants, and antihistamines, but standard therapies are often associated with several side effects. A new class of medical devices, based on bio-mechanically innovative triggers, has been proven to have a good clinical effectiveness with lower adverse reactions, particularly over prolonged administration periods. The present study aims at evaluating the economic impact of rhinitis, with respect to direct and indirect costs, and analysing the use of the medical device Narivent® compared to standard therapies to manage the symptoms of this illness. Methods: Via a Monte Carlo simulation study, data on disease prevalence, drug prescription and cost of both the specific therapeutic approach and the adverse events treatment will be combined to provide an estimate of the overall cost of the pharmacotherapy as compared with Narivent®. Results: Lowering the impact of adverse reactions related to standard therapy through the use of novel therapeutic approaches like Narivent®, might reduce the overall burden of rhinitis by about 5 billion per year. Conclusion: The use of the medical device Narivent®, as an alternative approach to manage symptoms associated with rhinitis, may contribute to bring down its costs by about 3.5% yearly as compared to the standard therapy.

AB - Rationale and aim: Upper airway disorders, like allergic and non-allergic rhinitis, are common nasal conditions affecting millions of individuals worldwide. The prevalence of allergic rhinitis (AR), in particular, has been increasing in the last decades. The pervasiveness of this disorder therefore imposes a large burden both on individual patients and the society. A wide range of drugs exists for symptomatic treatment of rhinitis, such as corticosteroids, decongestants, and antihistamines, but standard therapies are often associated with several side effects. A new class of medical devices, based on bio-mechanically innovative triggers, has been proven to have a good clinical effectiveness with lower adverse reactions, particularly over prolonged administration periods. The present study aims at evaluating the economic impact of rhinitis, with respect to direct and indirect costs, and analysing the use of the medical device Narivent® compared to standard therapies to manage the symptoms of this illness. Methods: Via a Monte Carlo simulation study, data on disease prevalence, drug prescription and cost of both the specific therapeutic approach and the adverse events treatment will be combined to provide an estimate of the overall cost of the pharmacotherapy as compared with Narivent®. Results: Lowering the impact of adverse reactions related to standard therapy through the use of novel therapeutic approaches like Narivent®, might reduce the overall burden of rhinitis by about 5 billion per year. Conclusion: The use of the medical device Narivent®, as an alternative approach to manage symptoms associated with rhinitis, may contribute to bring down its costs by about 3.5% yearly as compared to the standard therapy.

KW - Allergic rhinitis costs

KW - Burden of rhinitis

KW - Cost impact analysis

KW - Non allergic rhinitis costs

UR - http://www.scopus.com/inward/record.url?scp=84867518549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867518549&partnerID=8YFLogxK

U2 - 10.2174/1875181401204010061

DO - 10.2174/1875181401204010061

M3 - Article

VL - 4

SP - 61

EP - 65

JO - Open Medical Devices Journal

JF - Open Medical Devices Journal

SN - 1875-1814

IS - SPL. ISS.

ER -